Congratulations to Apexian Pharmaceuticals, which licenses technology through the Indiana University Innovation and Commercialization Office. Mark R. Kelley, Apexian Pharmaceuticals’ chief scientific officer, is the Betty and Earl Herr Chair in Pediatric Oncology Research and a professor in the Department of Biochemistry and Molecular Biology and the Department of Pharmacology and Toxicology at the Indiana University School of Medicine.
Officials announced the company has opened a clinical trial for patients with advanced solid tumors. The study involves APX3330, which inhibits a protein that plays a critical role in promoting and maintaining a variety of cancers.
“The initiation of the APX3330 study is a significant step forward in Apexian’s mission to develop safe and effective treatments for cancer patients,” said Steve Carchedi, president and CEO of Apexian Pharmaceuticals. “Despite recent advancements in cancer treatments, there continues to be a need for treatments that improve the survival of cancer patients. Apexian is committed to ‘moving mountains’ to help these patients.”
A news release with quotes from Carchedi and Dr. Richard Messmann, Apexian Pharmaceuticals’ chief medical officer, is available on Apexian Pharmaceuticals’ website.